The escalating global burden of antimicrobial resistance, complex oncological disorders, and chronic inflammatory diseases necessitates innovative therapeutic discovery strategies beyond conventional synthetic chemistry platforms. Medicinal plants represent an underexploited reservoir of structurally diverse bioactive compounds with validated ethnopharmacological foundations, yet their translation into clinically viable drug leads remains constrained by methodological inefficiencies, rediscovery of known metabolites, and reproducibility challenges. This article delineates contemporary bio-prospecting pipelines that integrate ethnopharmacology-guided selection, advanced metabolomics-enabled dereplication, and rigorous translational validation frameworks to accelerate the identification of novel phytochemical leads. The systematic workflow encompasses strategic plant selection through chemotaxonomic and traditional knowledge integration, optimized extraction and bioassay-guided fractionation protocols, high-resolution analytical characterization via LC-MS/MS molecular networking and NMR spectroscopy, and mechanistic pharmacological profiling across antimicrobial, anticancer, and anti-inflammatory targets. Critical emphasis is placed on early ADMET screening, cytotoxicity assessment, and lead optimization strategies to ensure translational readiness. Emerging technologies including artificial intelligence-driven compound prediction, automated fractionation platforms, and multi-omics integration are revolutionizing dereplication efficiency and hit-to-lead conversion rates. Sustainable sourcing frameworks, intellectual property considerations, and reproducibility standardization remain paramount for ethical and scalable natural product drug discovery, positioning medicinal plant bio-prospecting as a cornerstone strategy for next-generation therapeutic innovation.